
In hopes of decreasing opioid abuse, addictions, and overdose deaths, FDA this week announced safety-labeling changes for all extended-release and long-acting opioid analgesics used to treat pain. FDA has also added new postmarket study requirements for opioids such as morphine, oxycodone, and fentanyl.